Laboratory evaluation of pheochromocytoma and paraganglioma

Clinical Chemistry

Volumn 60, Issue 12, 2014, Pages 1486-1499

  Eisenhofer, Graeme ^a   Peitzsch, Mirko ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METADRENALIN; 3-METHOXYTYRAMINE; DOPAMINE; NORMETADRENALIN;

ADRENERGIC SYSTEM; ANALYTIC METHOD; CANCER SCREENING; CHROMAFFIN CELL; FAMILIAL CANCER; FOLLOW UP; HUMAN; IMMUNOASSAY; LABORATORY DIAGNOSIS; LABORATORY TEST; LIQUID CHROMATOGRAPHY; METASTASIS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROBABILITY; REFERENCE VALUE; REVIEW; SCREENING TEST; TANDEM MASS SPECTROMETRY; TUMOR DIAGNOSIS; TUMOR LOCALIZATION; TUMOR VOLUME; ADRENAL GLAND NEOPLASMS; ANALOGS AND DERIVATIVES; BLOOD; DIAGNOSTIC PROCEDURE; URINE;

ADRENAL GLAND NEOPLASMS; CLINICAL LABORATORY TECHNIQUES; DOPAMINE; HUMANS; METANEPHRINE; NORMETANEPHRINE; PARAGANGLIOMA; PHEOCHROMOCYTOMA;

EID: 84924454825     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2014.224832     Document Type: Review

References (78)

1. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005;366:665-75.
2. Manger WM. The protean manifestations of pheochromocytoma. Horm Metab Res 2009;41: 658-63.
3. Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A. Cardiovascular manifestations of phaeochromocytoma. J Hypertens 2011;29:2049-60.
4. Rosano TG, Swift TA, Hayes LW. Advances in catecholamine and metabolite measurements for diagnosis of pheochromocytoma. Clin Chem 1991;37:1854-67.
5. Bravo EL, Tarazi RC, Gifford RW, Stewart BH. Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications. NEJM 1979;301:682- 6.
6. Lenders JW, Eisenhofer G, Armando I, Keiser HR, Goldstein DS, Kopin IJ. Determination of metanephrines in plasma by liquid chromatography with electrochemical detection. Clin Chem 1993; 39:97-103.
7. Eisenhofer G, Huynh TT, Hiroi M, Pacak K. Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Rev Endocr Metab Disord 2001;2: 297-311.
8. Lenders JWM, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99:1915- 42.
9. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002;287:1427-34.
10. Unger N, Pitt C, Schmidt IL, Walz MK, Schmid KW, Philipp T, et al. Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol 2006;154:409 -17.
11. Hickman PE, Leong M, Chang J, Wilson SR, Mc-Whinney B. Plasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of phaeochromocytoma. Pathology 2009; 41:173-7.
12. Pussard E, Chaouch A, Said T. Radioimmunoassay of free plasma metanephrines for the diagnosis of catecholamine-producing tumors. Clin Chem Lab Med 2014;52:437- 44.
13. Kudva YC, Sawka AM, Young WF Jr. Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: The mayo clinic experience. J Clin Endocrinol Metab 2003;88:4533-9.
14. Eisenhofer G, Pacak K, Maher ER, Young WF, de Krijger RR. Pheochromocytoma. Clin Chem 2013; 59:466 -72.
15. Lagerstedt SA, O'Kane DJ, Singh RJ. Measurement of plasma free metanephrine and normetanephrine by liquid chromatography-tandem mass spectrometry for diagnosis of pheochromocytoma. Clin Chem 2004;50:603-11.
16. Whiting MJ. Simultaneous measurement of urinary metanephrines and catecholamines by liquid chromatography with tandem mass spectrometric detection. Ann Clin Biochem 2009;46:129 -36.
17. Grebe SK, Singh RJ. LC-MS/MS in the clinical laboratory-where to from here? Clin Biochem Rev 2011;32:5-31.
18. Peitzsch M, Pelzel D, Glockner S, Prejbisz A, Fassnacht M, Beuschlein F, et al. Simultaneous liquid chromatography tandem mass spectrometric determination of urinary free metanephrines and catecholamines, with comparisons of free and deconjugated metabolites. Clin Chim Acta 2013;418:50-8.
19. Peitzsch M, Prejbisz A, Kroiss M, Beuschlein F, Arlt W, Januszewicz A, et al. Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma. Ann Clin Biochem 2013;50:147-55.
20. Goldstein DS, Swoboda KJ, Miles JM, Coppack SW, Aneman A, Holmes C, et al. Sources and physiological significance of plasma dopamine sulfate. J Clin Endocrinol Metab 1999;84:2523- 31.
21. Simonin J, Gerber-Lemaire S, Centeno C, Seghezzi C, Iglesias K, Abid K, Grouzmann E. Synthetic calibrators for the analysis of total metanephrines in urine: revisiting the conditions of hydrolysis. Clin Chim Acta 2012;413:998 -1003.
22. Glauser M, Metrailler M, Gerber-Lemaire S, Centeno C, Seghezzi C, Dunand M, et al. Enzyme and acid deconjugation of plasma sulfated metanephrines. Clin Chim Acta 2014;430:125- 8.
23. Davison AS. Urinary free metanephrines and suitability of available quality control material. Clin Chim Acta 2013;424:83- 4.
24. Davidson DF. Phaeochromocytoma with normal urinary catecholamines: The potential value of urinary free metadrenalines. Ann Clin Biochem 2002;39:557- 66.
25. Boyle JG, Davidson DF, Perry CG, Connell JM. Comparison of diagnostic accuracy of urinary free metanephrines, vanillyl mandelic acid, and catecholamines and plasma catecholamines for diagnosis of pheochromocytoma. J Clin Endocrinol Metab 2007;92:4602- 8.
26. Pamporaki C, Därr R, Bursztyn M, Glockner S, Bornstein SR, Lenders JW, et al. Plasma-free vs deconjugated metanephrines for diagnosis of phaeochromocytoma. Clin Endocrinol 2013;79: 476-83.
27. Pillai D, Callen S. Pilot quality assurance programme for plasma metanephrines. Ann Clin Biochem 2010;47:137- 42.
28. Peaston RT, Graham KS, Chambers E, van der Molen JC, Ball S. Performance of plasma free metanephrines measured by liquid chromatography-tandem mass spectrometry in the diagnosis of pheochromocytoma. Clin Chim Acta 2010;411:546 -52.
29. Mullins F, O'Shea P, Fitzgerald R, Tormey W. Enzyme-linked immunoassay for plasma-free metanephrines in the biochemical diagnosis of phaeochromocytoma in adults is not ideal. Clin Chem Lab Med 2011;50:105-10.
30. Willemsen JJ, Sweep CG, Lenders JW, Ross HA. Stability of plasma free metanephrines during collection and storage as assessed by an optimized HPLC method with electrochemical detection. Clin Chem 2003;49:1951-3.
31. Willemsen JJ, Ross HA, Lenders JW, Sweep FC. Stability of urinary fractionated metanephrines and catecholamines during collection, shipment, and storage of samples. Clin Chem 2007;53:268- 72.
32. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, et al. Pheochromocytoma: recommendations for clinical practice from the first international symposium. Nat Clin Pract Endocrinol Metab 2007;3: 92-102.
33. Därr R, Pamporaki C, Peitzsch M, Miehle K, Prejbisz A, Peczkowska M, et al. Biochemical diagnosis of phaeochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. Clin Endocrinol 2014;80:478 - 86.
34. Eisenhofer G, Friberg P, Pacak K, Goldstein DS, Murphy DL, Tsigos C, et al. Plasma metadrenalines: Do they provide useful information about sympatho-adrenal function and catecholamine metabolism? Clin Sci (Lond) 1995;88:533- 42.
35. Sawka AM, Thabane L, Gafni A, Levine M, Young WF Jr. Measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: can specificity be improved by adjustment for age? BMC Endocr Disord 2005;5:1.
36. Eisenhofer G, Lattke P, Herberg M, Siegert G, Qin N, Därr R, et al. Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma. Ann Clin Biochem 2013; 50:62-9.
37. Kairisto V, Koskinen P, Mattila K, Puikkonen J, Virtanen A, Kantola I, Irjala K. Reference intervals for 24-h urinary normetanephrine, metanephrine, and 3-methoxy-4-hydroxymandelic acid in hypertensive patients. Clin Chem 1992;38:416 -20.
38. Weise M, Merke DP, Pacak K, Walther MM, Eisenhofer G. Utility of plasma free metanephrines for detecting childhood pheochromocytoma. J Clin Endocrinol Metab 2002;87:1955- 60.
39. Fitzgibbon M, FitzGerald RJ, Tormey WP, O'Meara A, Kenny D. Reference values for urinary HMMA, HVA, noradrenaline, adrenaline, and dopamine excretion in children using random urine samples and HPLC with electrochemical detection. Ann Clin Biochem 1992;29:400-4.
40. Pussard E, Neveux M, Guigueno N. Reference intervals for urinary catecholamines and metabolites from birth to adulthood. Clin Biochem 2009;42:536 -9.
41. Griffin A, O'Shea P, FitzGerald R, O'Connor G, Tormey W. Establishment of a paediatric agerelated reference interval for the measurement of urinary total fractionated metanephrines. Ann Clin Biochem 2011;48:41- 4.
42. Davidson DF, Hammond PJ, Murphy DL, Carachi R. Age-related medical decision limits for urinary free (unconjugated) metadrenalines, catecholamines and metabolites in random urine specimens from children. Ann Clin Biochem 2011;48:358 - 66.
43. Yu R, Wei M. False positive test results for pheochromocytoma from 2000 to 2008. Exp Clin Endocrinol Diabetes 2010;118:577- 85.
44. Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR, Pacak K. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003;88:2656-66.
45. Lenders JW, Willemsen JJ, Eisenhofer G, Ross HA, Pacak K, Timmers HJ, Sweep CG. Is supine rest necessary before blood sampling for plasma metanephrines? Clin Chem 2007;53:352- 4.
46. de Jong WH, Eisenhofer G, Post WJ, Muskiet FA, de Vries EG, Kema IP. Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors. J Clin Endocrinol Metab 2009;94:2841-9.
47. Deutschbein T, Unger N, Jaeger A, Broecker- Preuss M, Mann K, Petersenn S. Influence of various confounding variables and storage conditions on metanephrine and normetanephrine levels in plasma. Clin Endocrinol 2010;73:153- 60.
48. Pamporaki C, Bursztyn M, Reimann M, Ziemssen T, Bornstein SR, Sweep FC, et al. Seasonal variation in plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma. Eur J Endocrinol 2014;170:349 -57.
49. Anas SS, Vasikaran SD. An audit of management of patients with borderline increased plasma-free metanephrines. Ann Clin Biochem 2010;47: 554-8.
50. Peaston RT, Lennard TW, Lai LC. Overnight excretion of urinary catecholamines and metabolites in the detection of pheochromocytoma. J Clin Endocrinol Metab 1996;81:1378-84.
51. Peaston RT, Weinkove C. Measurement of catecholamines and their metabolites. Ann Clin Biochem 2004;41:17-38.
52. Harding JL, Yeh MW, Robinson BG, Delbridge LW, Sidhu SB. Potential pitfalls in the diagnosis of phaeochromocytoma. Med J Aust 2005;182:637- 40.
53. Neary NM, King KS, Pacak K. Drugs and pheochromocytoma-don't be fooled by every elevated metanephrine. NEJM 2011;364:2268- 70.
54. Lefebvre H, Noblet C, Moore N, Wolf LM. Pseudophaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline. Clin Endocrinol 1995;42: 95-8.
55. Davidson DF, Grosset K, Grosset D. Parkinson's disease: The effect of L-dopa therapy on urinary free catecholamines and metabolites. Ann Clin Biochem 2007;44:364-8.
56. Eisenhofer G, Brown S, Peitzsch M, Pelzel D, Lattke P, Glockner S, et al. Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine. Ann Clin Biochem 2014;51:38-46.
57. Davidson FD. Paracetamol-associated interference in an HPLC-ECD assay for urinary free metadrenalines and catecholamines. Ann Clin Biochem 2004;41:316 -20.
58. Ito T, Imai T, Kikumori T, Shibata A, Horiba T, Kobayashi H, et al. Adrenal incidentaloma: review of 197 patients and report of a drug-related false-positive urinary normetanephrine result. Surg Today 2006;36:961-5.
59. Bouhanick B, Fauvel J, Pont F. Biochemical misdiagnosis of pheochromocytoma in patients treated with sulfasalazine. JAMA 2010;304: 1898 -901.
60. van Laarhoven HW, Willemsen JJ, Ross HA, Beex LV, Lenders JW, Sweep FC. Pitfall in HPLC assay for urinary metanephrines: An unusual type of interference caused by methenamine intake. Clin Chem 2004;50:1097-9.
61. Madhavaram H, Woollard GA. Interference from Indian diet on the internal standard in a commercial method for the measurement of urinary metanephrines by high-performance liquid chromatography with electrochemical detection. Ann Clin Biochem 2014;51:400 -5.
62. Twentyman JM, Cradic KW, Singh RJ, Grebe SK. Ionic cross talk can lead to overestimation of 3-methoxytyramine during quantification of metanephrines by mass spectrometry. Clin Chem 2012;58:1156 - 8.
63. Dunand M, Donzelli M, Rickli A, Hysek CM, Liechti ME, Grouzmann E. Analytical interference of 4-hydroxy-3-methoxymethamphetamine with the measurement of plasma free normetanephrine by ultra-high pressure liquid chromatography-tandem mass spectrometry. Clin Biochem 2014;47:1121-3.
64. Eisenhofer G, Goldstein DS, Sullivan P, Csako G, Brouwers FM, Lai EW, et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab 2005;90:2068- 75.
65. Timmers HJ, Pacak K, Huynh TT, Abu-Asab M, Tsokos M, Merino MJ, et al. Biochemically silent abdominal paragangliomas in patients with mutations in the SDHB gene. J Clin Endocrinol Metab 2008;93:4826 -32.
66. Hernandez FC, Sanchez M, Alvarez A, Diaz J, Pascual R, Perez M, et al. A five-year report on experience in the detection of pheochromocytoma. Clin Biochem 2000;33:649 -55.
67. Vaclavik J, Stejskal D, Lacnak B, Lazarova M, Jedelsky L, Kadalova L, et al. Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients. J Hypertens 2007;25: 1427-31.
68. Brain KL, Kay J, Shine B. Measurement of urinary metanephrines to screen for pheochromocytoma in an unselected hospital referral population. Clin Chem 2006;52:2060-4.
69. Terzolo M, Bovio S, Pia A, Reimondo G, Angeli A. Management of adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab 2009;23:233- 43.
70. Howe JR, Norton JA, Wells SA Jr. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2a: Results of long-term follow-up. Surgery 1993;114:1070 -7.
71. Amar L, Fassnacht M, Gimenez-Roqueplo AP, Januszewicz A, Prebjbisz A, Timmers H, Plouin PF. Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Horm Metab Res 2012;44:385-9.
72. Stenstrom G, Waldenstrom J. Positive correlation between urinary excretion of catecholamine metabolites and tumour mass in pheochromocytoma. Results in patients with sustained and paroxysmal hypertension and multiple endocrine neoplasia. Acta Med Scand 1985;217:73-7.
73. Eisenhofer G, Lenders JW, Goldstein DS, Mannelli M, Csako G, Walther MM, et al. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem 2005;51:735- 44.
74. Eisenhofer G, Lenders JW, Timmers H, Mannelli M, Grebe SK, Hofbauer LC, et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem 2011;57:411-20.
75. Davidson DF, Bradshaw N, Perry CG, Lindsay R, Freel EM. Urinary free (unconjugated) metadrenalines in different hereditary forms of catecholaminesecreting phaeochromocytoma/paraganglioma. Ann Clin Biochem 2012;49:486-90.
76. John H, Ziegler WH, Hauri D, Jaeger P. Pheochromocytomas: can malignant potential be predicted? Urology 1999;53:679-83.
77. van der Harst E, de Herder WW, de Krijger RR, Bruining HA, Bonjer HJ, Lamberts SW, et al. The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur J Endocrinol 2002; 147:85-94.
78. Eisenhofer G, Lenders JW, Siegert G, Bornstein SR, Friberg P, Milosevic D, et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status Eur J Cancer 2012;48:1739 - 49.